DC Chemicals Limited
China
Product Name: U-46619
Price: $Inquiry/100mg $Inquiry/250mg $Inquiry/500mg
Purity: 98.0%
Stocking Period: 3 Day
Contact: Tony Cao

56985-40-1

56985-40-1 structure

56985-40-1 structure

Name: U-46619
Chemical Name: 9,11-Dideoxy-11α,9α-epoxymethanoprostaglandin F2α
CAS Number: 56985-40-1
Molecular Formula: C₂₁H₃₄O₄
Molecular Weight: 350.492
Catalog: Signaling Pathways GPCR/G Protein Prostaglandin Receptor
Create Date: 2018-12-22 11:25:00
Modify Date: 2024-04-03 12:44:01
U-46619 (9,11-Methanoepoxy PGH2) is a stable analogue of thromboxane A2 (TXA2) and acts as a potent TXA2 agonist[1].

Name	9,11-Dideoxy-11α,9α-epoxymethanoprostaglandin F2α
Synonyms	5-Heptenoic acid, 7-[(1R,4S,5S,6R)-6-[(1E,3S)-3-hydroxy-1-octen-1-yl]-2-oxabicyclo[2.2.1]hept-5-yl]-, (5Z)- (5Z)-7-{(1R,4S,5S,6R)-6-[(1E,3S)-3-Hydroxy-1-octen-1-yl]-2-oxabicyclo[2.2.1]hept-5-yl}-5-heptenoic acid MFCD00135238 U 46619,(5Z)-7-[(1R,4S,5S,6R)-6-[(1E,3S)-3-Hydroxy-1-octenyl]-2-oxabicyclo[2.2.1]hept-5-yl]-5-heptenoicacid

Description	U-46619 (9,11-Methanoepoxy PGH2) is a stable analogue of thromboxane A2 (TXA2) and acts as a potent TXA2 agonist[1].
Related Catalog	Research Areas >> Cardiovascular Disease Signaling Pathways >> GPCR/G Protein >> Prostaglandin Receptor
Target	TXA2[1]
In Vitro	U-46619 (1 nM-10 μM) causes platelets shape change and aggregation in a concentration-dependent manner, and with EC50s of 0.58 μM and 0.013 μM for aggregation and shape change, respectively[1]. U-46619 (10 nM-10 μM) increases internal Ca2+ concentration ([Ca2+]i) and activates phosphoinositide (PI) hydrolysis in a concentration-dependent manner with a similar concentration-dependency[1]. U-46619 (3 nM-10 μM) also activates GTPase concentration-dependently in the membranes derived from platelets[1]. U-46619 improves the differentiation efficiency of human induced pluripotent stem cells into endothelial cells by activating both p38MAPK and ERK1/2 signaling pathways[2].
In Vivo	U-46619 (5 μg/kg; i.v.) increases blood pressure in male spontaneously hypertensive rats (SHR)[3]. Animal Model: 12-15 weeks-old male and female SHR[2] Dosage: 5 μg/kg Administration: Intravenous injection Result: Induceed a significant increase of MABP after 1 min in male SHR.
References	[1]. Ohkubo S, et al. Thromboxane A2-mediated shape change: independent of Gq-phospholipase C--Ca2+ pathway in rabbit platelets. Br J Pharmacol. 1996 Mar;117(6):1095-104. [2]. Su L, et al. The prostaglandin H2 analog U-46619 improves the differentiation efficiency of human induced pluripotent stem cells into endothelial cells by activating both p38MAPK and ERK1/2 signaling pathways. Stem Cell Res Ther. 2018 Nov 15;9(1):313. [3]. Schirner M, et al. U 46619 induces different blood pressure effects in male and female spontaneously hypertensive rats (SHR). Prostaglandins Leukot Essent Fatty Acids. 1993 Jun;48(6):469-73.

Density	1.1±0.1 g/cm3
Boiling Point	519.7±30.0 °C at 760 mmHg
Molecular Formula	C₂₁H₃₄O₄
Molecular Weight	350.492
Flash Point	176.1±18.1 °C
Exact Mass	350.245697
PSA	66.76000
LogP	3.90
Vapour Pressure	0.0±3.1 mmHg at 25°C
Index of Refraction	1.548

CHEMICAL IDENTIFICATION

RTECS NUMBER :: MJ9681090

CHEMICAL NAME :: 5-Heptenoic acid, 7-(6-(3-hydroxy-1-octenyl)-2-oxabicyclo(2.2.1)hept-5- yl)-, (1R-(1-alpha, 4-alpha,5-beta(Z),6-alpha(1E,3S*)))-

CAS REGISTRY NUMBER :: 56985-40-1

LAST UPDATED :: 198306

DATA ITEMS CITED :: 1

MOLECULAR FORMULA :: C21-H34-O4

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intravenous

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 66 ug/kg

TOXIC EFFECTS :: Lungs, Thorax, or Respiration - dyspnea Lungs, Thorax, or Respiration - other changes

REFERENCE :: JPETAB Journal of Pharmacology and Experimental Therapeutics. (Williams & Wilkins Co., 428 E. Preston St., Baltimore, MD 21202) V.1- 1909/10- Volume(issue)/page/year: 224,369,1983

Symbol	GHS02, GHS07
Signal Word	Danger
Hazard Statements	H225-H319-H336
Supplemental HS	Repeated exposure may cause skin dryness or cracking.
Precautionary Statements	P210-P280-P304 + P340 + P312-P305 + P351 + P338-P337 + P313-P403 + P235
Personal Protective Equipment	Eyeshields;Faceshields;full-face respirator (US);Gloves;multi-purpose combination respirator cartridge (US);type ABEK (EN14387) respirator filter
Hazard Codes	F;Xi
Risk Phrases	R11;R36;R66;R67
Safety Phrases	S16;S26
RIDADR	UN 1231 3/PG 2